Blood Cancer J 2021 May 12
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Related Questions
New comment by Medical Oncologist at Yale Cancer Center ( July 4, 2021)
While I generally agree with the above, a recent small study of 9 patients that were previously treated with daratumumab did demonstrate an overall response rate of 77% with i...